You get your HbA1c results back and your doctor says your blood sugar control looks great—or maybe concerning. But what if the number on that report doesn't reflect reality? For millions of people carrying hemoglobin variants, this is a genuine possibility.

Hemoglobin—the oxygen-carrying protein packed inside every red blood cell—isn't identical in everyone. Genetic variations can alter its molecular structure, sometimes causing disease, sometimes producing no symptoms at all, but frequently interfering with laboratory tests that assume a standard hemoglobin profile.

Understanding hemoglobin variants matters on two fronts. First, some variants carry direct health consequences that deserve monitoring. Second, and perhaps more commonly overlooked, they can distort routine lab work in ways that lead to misdiagnosis or inappropriate treatment. Knowing whether you carry a variant—and what it means for your numbers—is one of the most underappreciated aspects of personal health literacy.

Hemoglobin is built from four protein chains—typically two alpha and two beta—each encoded by specific genes. A single change in the DNA sequence for any of these chains can produce a hemoglobin variant. More than a thousand variants have been cataloged worldwide, though only a handful are common enough to affect routine medical care.

The most well-known is hemoglobin S, the variant behind sickle cell disease. In its heterozygous form—sickle cell trait—a person carries one normal beta-globin gene and one sickle variant. They typically produce enough normal hemoglobin to avoid the painful crises of full sickle cell disease, but their blood still contains a meaningful proportion of hemoglobin S. Hemoglobin C, hemoglobin E, and hemoglobin D are other relatively common variants, each arising from a different point mutation in the beta-globin gene.

Thalassemia traits work differently. Rather than producing an abnormal hemoglobin molecule, thalassemias reduce the quantity of one type of globin chain. Alpha thalassemia trait means fewer alpha chains are made; beta thalassemia trait means fewer beta chains. The result is smaller, paler red blood cells and sometimes mild anemia—but the hemoglobin molecules that do get assembled may still be structurally normal.

This distinction between structural variants and production variants is crucial. Structural variants like hemoglobin S change how the molecule behaves chemically. Production variants like thalassemia traits change the balance of normal components. Both can affect lab testing, but through entirely different mechanisms—and recognizing which category a variant falls into determines what adjustments are needed.

Takeaway

Hemoglobin variants aren't a single phenomenon. Some alter the molecule's shape, others reduce its quantity. Knowing which type you carry changes both the health implications and the way your lab results should be read.

HbA1c is the cornerstone of diabetes monitoring. It measures glycated hemoglobin—glucose molecules that have attached to hemoglobin over the lifespan of a red blood cell, roughly 90 to 120 days. The result provides a rolling average of blood sugar control. Except when it doesn't.

Many HbA1c assays work by separating hemoglobin types based on their electrical charge or molecular structure. Hemoglobin variants can co-migrate with or be misidentified as glycated hemoglobin, producing falsely elevated or falsely low results depending on the variant and the assay method. Hemoglobin S, C, and E are particularly notorious for this interference. A person with well-controlled blood sugar could receive an alarming HbA1c—or someone with genuinely high glucose could be falsely reassured.

Thalassemia traits introduce a different problem. Because they shorten red blood cell lifespan, hemoglobin has less time to accumulate glucose. The result: HbA1c reads lower than actual average blood sugar. This isn't an assay error—it's a biological reality that the test wasn't designed to accommodate. For someone with beta thalassemia trait, an HbA1c of 6.0% might correspond to an actual average glucose level that would produce a 6.5% reading in someone with normal hemoglobin.

The solution isn't to abandon HbA1c but to know when alternatives are needed. Fructosamine measures glycated albumin over a shorter window and isn't affected by hemoglobin variants. Continuous glucose monitoring provides direct measurements entirely independent of hemoglobin. Some newer HbA1c assays have been validated against specific variants. The critical step is ensuring your healthcare provider knows your hemoglobin status before interpreting any glycated hemoglobin result.

Takeaway

An HbA1c result is only as reliable as the hemoglobin it's measuring. If you carry a variant, ask your provider whether your assay method is affected—and whether fructosamine or continuous glucose monitoring would give a truer picture.

The word "variant" can trigger alarm, but most hemoglobin variants in their trait form—meaning one affected gene and one normal gene—cause little or no direct health consequence. Sickle cell trait affects roughly 8% of Black Americans and over 300 million people worldwide, the vast majority of whom live without sickle cell disease symptoms. Hemoglobin C trait and hemoglobin E trait are similarly benign in most clinical contexts.

That said, "benign" doesn't mean "irrelevant." Sickle cell trait carries a small but real risk of complications under extreme physiological stress—high altitude, intense exertion, severe dehydration. Rare cases of splenic infarction and exertional rhabdomyolysis have been documented. These events are uncommon enough that sickle cell trait is not considered a disease, but they're significant enough to warrant awareness, particularly for athletes and military personnel.

Beta thalassemia trait typically produces a mild microcytic anemia that can be mistaken for iron deficiency. The distinction matters enormously: iron supplementation won't correct thalassemia-related anemia, and unnecessary iron loading carries its own risks. A complete blood count showing small red cells with a normal or elevated red blood cell count is a classic thalassemia trait pattern—quite different from iron deficiency, where the cell count drops.

Perhaps the most important clinical significance of carrying any hemoglobin trait is genetic. When two carriers of the same variant have children, there's a one-in-four chance each pregnancy will produce a child with the full disease—sickle cell disease, hemoglobin SC disease, beta thalassemia major. Knowing your carrier status isn't just about interpreting your own lab work. It's information that may profoundly matter for family planning.

Takeaway

Carrying a hemoglobin trait rarely means you have a disease, but it always means you have information worth knowing—for your own lab accuracy, for situations of physical extremes, and for the health of future generations.

Hemoglobin variants sit at a fascinating intersection of genetics, laboratory science, and everyday healthcare. They remind us that no test result exists in a vacuum—every number on a lab report carries assumptions about the biology behind it.

If you don't know your hemoglobin status, a hemoglobin electrophoresis or HPLC test can identify most common variants. It's typically a one-time test with lifelong relevance, particularly if you have African, Mediterranean, Middle Eastern, or Southeast Asian ancestry.

The goal isn't anxiety—it's calibration. Know your variant status, share it with every provider who orders blood work, and ensure the tests meant to guide your care are actually reading your biology accurately.